Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation

Vaccine

Volumn 26, Issue 40, 2008, Pages 5223-5229

  Rosati, Margherita ^a   Valentin, Antonio ^a   Jalah, Rashmi ^a   Patel, Vainav ^a   von Gegerfelt, Agneta ^a   Bergamaschi, Cristina ^a   Alicea, Candido ^a   Weiss, Deborah ^b   Treece, Jim ^b   Pal, Ranajit ^b   Markham, Phillip D ^b   Marques, Ernesto T A ^c   August, J Thomas ^c   Khan, Amir ^d   Draghia Akli, Ruxandra ^d   Felber, Barbara K ^a   Pavlakis, George N ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b ADVANCED BIOSCIENCE LABORATORIES INC   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VGX Pharmaceuticals Inc   (United States)

Author keywords

Central memory; DNA vaccine; Effector memory; Electroporation; HIV; Immune response; Intramuscular injection; Rhesus macaque; SIV; T cell subset

Indexed keywords

ANTIRETROVIRUS AGENT; DNA VACCINE; EMTRICITABINE; GAG PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; INTERLEUKIN 15; TENOFOVIR; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CENTRAL MEMORY CELL; CORRELATION ANALYSIS; DNA IMMUNIZATION; DNA VECTOR; DRUG DOSE REDUCTION; DRUG EFFICACY; EFFECTOR MEMORY CELL; ELECTROPORATION; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; IMMUNOGENICITY; IN VIVO STUDY; MACACA; MEMORY T LYMPHOCYTE; NONHUMAN; PHENOTYPE; PLASMID; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE SUBPOPULATION; VIREMIA;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; ELECTROPORATION; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HUMANS; IMMUNOLOGIC MEMORY; INJECTIONS, INTRAMUSCULAR; MACACA MULATTA; PLASMIDS; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINES, DNA; VIREMIA;

EID: 50849121388     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.090     Document Type: Article

References (36)

1. Graham B.S., Koup R.A., Roederer M., Bailer R.T., Enama M.E., Moodie Z., et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 194 12 (2006) 1650-1660
2. McMichael A.J. HIV vaccines. Annu Rev Immunol 24 (2006) 227-255
3. Brave A., Ljungberg K., Wahren B., and Liu M.A. Vaccine delivery methods using viral vectors. Mol Pharm 4 1 (2007) 18-32
4. Dale C.J., Thomson S., De Rose R., Ranasinghe C., Medveczky C.J., Pamungkas J., et al. Prime-boost strategies in DNA vaccines. Methods Mol Med 127 (2006) 171-197
5. Duerr A., Wasserheit J.N., and Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 43 4 (2006) 500-511
6. Girard M.P., Osmanov S.K., and Kieny M.P. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 24 19 (2006) 4062-4081
7. Hokey D.A., and Weiner D.B. DNA vaccines for HIV: challenges and opportunities. Springer Semin Immunopathol 28 3 (2006) 267-279
8. Liu M.A., Wahren B., and Karlsson Hedestam G.B. DNA vaccines: recent developments and future possibilities. Hum Gene Ther 17 11 (2006) 1051-1061
9. Lori F., Weiner D.B., Calarota S.A., Kelly L.M., and Lisziewicz J. Cytokine-adjuvanted HIV-DNA vaccination strategies. Springer Semin Immunopathol 28 3 (2006) 231-238
10. Lu S. Combination DNA plus protein HIV vaccines. Springer Semin Immunopathol 28 3 (2006) 255-265
11. Rodriguez-Chavez I.R., Allen M., Hill E.L., Sheets R.L., Pensiero M., Bradac J.A., et al. Current advances and challenges in HIV-1 vaccines. Curr HIV/AIDS Rep 3 1 (2006) 39-47
12. Thorner A.R., and Barouch D.H. HIV-1 vaccine development: progress and prospects. Curr Infect Dis Rep 9 1 (2007) 71-75
13. Prud'homme G.J., Glinka Y., Khan A.S., and Draghia-Akli R. Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 6 2 (2006) 243-273
14. Aihara H., and Miyazaki J. Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 16 9 (1998) 867-870
15. Widera G., Austin M., Rabussay D., Goldbeck C., Barnett S.W., Chen M., et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J Immunol 164 9 (2000) 4635-4640
16. Rizzuto G., Cappelletti M., Maione D., Savino R., Lazzaro D., Costa P., et al. Efficient and regulated erythropoietin production by naked DNA injection and muscle electroporation. Proc Natl Acad Sci USA 96 11 (1999) 6417-6422
17. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 6 4 (1999) 508-514
18. Santra S., Sun Y., Parvani J.G., Philippon V., Wyand M.S., Manson K., et al. Heterologous prime/boost immunization of rhesus monkeys by using diverse poxvirus vectors. J Virol 81 16 (2007) 8563-8570
19. Romano J.W., Shurtliff R.N., Dobratz E., Gibson A., Hickman K., Markham P.D., et al. Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J Virol Methods 86 1 (2000) 61-70
20. Patterson L.J., Malkevitch N., Venzon D., Pinczewski J., Gomez-Roman V.R., Wang L., et al. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 78 5 (2004) 2212-2221
21. Rosati M., von Gegerfelt A., Roth P., Alicea C., Valentin A., Robert-Guroff M., et al. DNA vaccines expressing different forms of SIV antigens decrease viremia upon SIVmac251 challenge. J Virol 79 13 (2005) 8480-8492
22. Schwartz S., Campbell M., Nasioulas G., Harrison J., Felber B.K., and Pavlakis G.N. Mutational inactivation of an inhibitory sequence in human immunodeficiency virus type 1 results in Rev-independent gag expression. J Virol 66 12 (1992) 7176-7182
23. Schwartz S., Felber B.K., and Pavlakis G.N. Distinct RNA sequences in the gag region of human immunodeficiency virus type 1 decrease RNA stability and inhibit expression in the absence of Rev protein. J Virol 66 1 (1992) 150-159
24. Schneider R., Campbell M., Nasioulas G., Felber B.K., and Pavlakis G.N. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 71 7 (1997) 4892-4903
25. Nasioulas G., Zolotukhin A.S., Tabernero C., Solomin L., Cunningham C.P., Pavlakis G.N., et al. Elements distinct from human immunodeficiency virus type 1 splice sites are responsible for the Rev dependence of env mRNA. J Virol 68 5 (1994) 2986-2993
26. Biragyn A., Tani K., Grimm M.C., Weeks S., and Kwak L.W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 17 3 (1999) 253-258
27. von Gegerfelt A.S., Rosati M., Alicea C., Valentin A., Roth P., Bear J., et al. Long-lasting decrease in viremia in macaques chronically infected with simian immunodeficiency virus SIVmac251 after therapeutic DNA immunization. J Virol 81 4 (2007) 1972-1979
28. Jalah R., Rosati R., Kulkarni V., Patel V., Bergamaschi C., Valentin A., et al. Efficient systemic expression of bioactive IL-15 In mice upon delivery of optimized DNA expression plasmids. DNA Cell Biol. 26 12 (2007) 827-840
29. Marques Jr. E.T., Chikhlikar P., de Arruda L.B., Leao I.C., Lu Y., Wong J., et al. HIV-1 p55Gag encoded in the lysosome-associated membrane protein-1 as a DNA plasmid vaccine chimera is highly expressed, traffics to the major histocompatibility class II compartment, and elicits enhanced immune responses. J Biol Chem 278 39 (2003) 37926-37936
30. de Arruda L.B., Chikhlikar P.R., August J.T., and Marques E.T. DNA vaccine encoding human immunodeficiency virus-1 Gag, targeted to the major histocompatibility complex II compartment by lysosomal-associated membrane protein, elicits enhanced long-term memory response. Immunology 112 1 (2004) 126-133
31. Chikhlikar P., de Arruda L.B., Maciel M., Silvera P., Lewis M.G., August J.T., et al. DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques. PLoS ONE 1 (2006) e135
32. Bergamaschi C., Rosati M., Jalah R., Valentin A., Kulkarni V., Alicea C., et al. Intracellular interaction of interleukin-15 with its receptor alpha during production leads to mutual stabilization and increased bioactivity. J Biol Chem 283 7 (2008) 4189-4199
33. Pachuk C.J., Ciccarelli R.B., Samuel M., Bayer M.E., Troutman R.D., Zurawski D.V., et al. Characterization of a new class of DNA delivery complexes formed by the local anesthetic bupivacaine. Biochim Biophys Acta 1468 1-2 (2000) 20-30
34. Luckay A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 81 10 (2007) 5257-5269
35. Sheets R.L., Stein J., Manetz T.S., Duffy C., Nason M., Andrews C., et al. Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts. Toxicol Sci 91 2 (2006) 610-619
36. Wang Z., Troilo P.J., Wang X., Griffiths T.G., Pacchione S.J., Barnum A.B., et al. Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation. Gene Ther 11 8 (2004) 711-721